Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Trial of Dolutegravir (DTG)-Based Antiretroviral Therapy vs. Standard of Care (SOC) in Children With HIV Infection Starting First-line or Switching to Second-line ART

NCT02259127 is registered in ClinicalTrials.gov with PENTA Foundation as lead sponsor.

NCT NCT02259127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02259127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Trial of Dolutegravir (DTG)-Based Antiretroviral Therapy vs. Standard of Care (SOC) in Children With HIV Infection Starting First-line or Switching to Second-line ART
Lead sponsor
PENTA Foundation
Phase
Phase 2/3
Overall status
Completed
Start date
September 20, 2016
Completion date
December 7, 2023
Enrollment
792 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection